Esperion Therapeutis.Inc. buy El_Zocko
Start price
29.09.15
/
50%
€20.64
Target price
20.10.16
€35.00
Performance (%)
-47.70%
End price
20.10.16
€10.79
Summary
This prediction ended on 20.10.16 with a price of €10.79. Massive losses of -47.70% were the result for the BUY prediction by El_Zocko. El_Zocko has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -22.166% | -22.166% | 19.452% | -59.417% |
| iShares Core DAX® | 0.191% | 4.892% | 22.046% | 64.626% |
| iShares Nasdaq 100 | -0.614% | 2.901% | 7.804% | 109.421% |
| iShares Nikkei 225® | 0.599% | 7.404% | 22.218% | 57.591% |
| iShares S&P 500 | -0.036% | 3.489% | 4.833% | 68.003% |
Comments by El_Zocko for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Schlimmer geht nimmer?
Hoffen wir es!!
(Laufzeit überschritten)